A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
Latest Information Update: 12 Dec 2025
At a glance
- Drugs Bomedemstat (Primary)
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Adverse reactions; Registrational
- Acronyms MK-3543-017; Shorespan-017
- Sponsors Imago BioSciences; Merck Sharp & Dohme
Most Recent Events
- 24 Nov 2025 According to a Merck and Co media release, data from this trial will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9.
- 27 May 2024 Status changed from not yet recruiting to recruiting.
- 02 Apr 2024 Status changed from planning to not yet recruiting.